Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, and Rana McKay, MD, University of California, San Diego Moores Cancer Center, discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma.